InflaRx N.V.

NASDAQ:IFRX  
2.59
-0.10 (-3.72%)
5:28:59 PM EDT: $2.57 -0.02 (-0.77%)
Products

InflaRx Submits Request For Emergency Use Authorization To US FDA

Published: 09/29/2022 13:32 GMT
InflaRx N.V. (IFRX) - Inflarx Submits Request for Emergency Use Authorization to US FDA for Vilobelimab for Treatment of Critically Ill Covid-19 Patients.
Inflarx NV Says Earns FDA Fast Track Designation for Vilobelimab to Treat Critically Ill Covid-19 Patients.
Inflarx NV Says Eua Submission for Vilobelimab, Based on Phase Iii Results in Critically Ill Covid-19 Patients.